2. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 51

3. Zumla A., Chan J.F., Azhar E.I., Hui D.S., Yuen K.Y. Coronaviruses – drug discovery and therapeutic options. Nat Rev Drug Discov 2016;15(5):327– 347. Doi: 10.1038/nrd.2015.37.

4. He F., Deng Y., Li W. Coronavirus Disease 2019: what we know? J Med Virol 2020

5. Yang Y., Peng F., Wang R., Guan K., Jiang T., Xu G., et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun 2020; 102434

6. Zumla A., Niederman M.S. The explosive epidemic outbreak of novel coronavirus disease 2019 (COVID-19) and the persistent threat of respiratory tract infectious diseases to global health security. Curr Opin Pulm Med 2020;26(3):193–196. Doi: 10.1097/MCP.0000000000000676.

7. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020

8. Gu J., Han B., Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020;158:1518–1519.

9. Lin L., Lu L., Cao W., Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection – a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020;9(1):727–732. Doi: 10.1080/22221751.2020.1746199.

10. Zou X., Chen K., Zou J., Han P., Hao J., Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020;14(2):185–192. Doi: 10.1007/s11684-020-0754-0

11. Yang X.H., Sun R.H., Chen D.C.

12. Fan С., Li K., Ding Ya., Lu W.L., Wang J. ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection. MedRxiv 2020. Doi: https://doi.org/10.1101/2020.02.12.20022418.

13. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhi bitor. Cell. 2020;181:271–280.e8.

14. Xu H., Zhong L., Deng J., Peng J., Dan H., Zeng X., et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12:1–5.

15. Urology. Russian clinical guidelines. Under the editorship of Yu.G. Alyaev,P.V. Glybochko, D.Yu. Pushkar. M.: GEOTAR-Media; 2018. 480 s. Russian (Урология. Российские клинические рекомендации. Под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. М.: ГЭОТАР-Медиа; 2018. 480 с.)

16. Gravas S., Cornu J.N, Drake M.J. et al. EAU guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). 2018. Available at: http://uroweb.org/guideline/ treatment-of-non-neurogenic male-luts/ Accessed 5 May 2019

17. Schaeffer A.J. Classification (Traditional and National Institutes of Health) and Demographics of Prostatitis. Urology. 2002;60(6 Suppl):5–6; discussion 6-7. Doi: 10.1016/s0090-4295(02)02292-6.

18. Kudryavcev Yu.V., Sivkov A.V. Morphological alteration in benign prostatic hyperplasia tissue. Experimental and clinical urology. 2010;1:8-22 Russian (Кудрявцев Ю.В., Сивков А.В. Морфологические изменения в ткани предстательной железы при доброкачественной гиперплазии. Экспериментальная и клиническая урология. 2010;1:8-22.)

19. Berry, S.J., Coffey, D.S., Walsh, P.C. and Ewing, L.L. (1984) The Development of Human Benign Prostatic Hyperplasia with Age. The Journal of Urology, 132, 474-479. https://doi.org/10.1016/S0022-5347(17)49698-4

20. Roehrborn C.G., Oyarzabal Perez I., Roos E.P., Calomfirescu N., Brotherton B., Wang F., Palacios J.M., Vasylyev A., Manyak M.J. Efficacy and safety ofa fixed-dose combination of dutasteride and tamsulosin treatment (Duodart) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;7. Doi: 10.1111/bju.13033

21. Li L.Q., Huang T., Wang Y.Q., Wang Z.P., Liang Y., Huang T.B., et al. COVID-patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92:577–583.

22. Liang X. Is COVID-19 more severe in older men? Postgrad Med J. 2020;96:426.

23. Mizumoto K., Kagaya K., Zarebski A., Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eur Surveill. 2020;25:2000180.

24. Nishiura H., Kobayashi T., Miyama T., Suzuki A., Jung S.-m., Hayashi K., et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020;94:154–155.

25. Can O, Erkoç M, Ozer M, Umeyir Karakanli M, Otunctemur A. The effect of COVID-19 on lower urinary tract symptoms in elderly men. Int J Clin Pract. 2021;75:e14110.

26. Kaya Y., Kaya C., Kartal T., Tahta T., Tokgöz V.Y. Could LUTS beearly symptoms of COVID-19. Int J Clin Pract. 2020;75:e13850.

27. Cohn JN. Role of the renin-angiotensin system in cardiovascular disease. Cardiovasc Drugs Ther. 2010;24:341–344.

28. Peach MюJ. Renin-angiotensin system: biochemistry and mechan isms of action. Physiol Rev. 1977;57:313–70.

29. Dinh D.T., Frauman A.G., Sourial M., Casley D.J., Johnston C.I., FabianiM.E. Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia. Endocrinology. 2001;142:1349–1356.

30. Nassis L., Frauman A.G., Ohishi M., Zhuo J., Casley D.J., Johnston C.I., et al. Localization of angiotensin-converting enzyme in the human prostate: pathological expression in benign prostatic hyperplasia. J Pathol. 2001;195:571–9.

31. Dinh D.T., Frauman A.G., Somers G.R., Ohishi M., Zhou J., Casley D.J., et al. Evidence for activation of the renin–angiotensin system in the human prostate: increased angiotensin II and reduced AT1 receptor expression in benign prostatic hyperplasia. J Pathol. 2002;196:213–9.

32. Singh Y., Gupta G., Sharma R., Matta Y., Mishra A., Pinto Td.J.A., et al. Embarking effect of ACE2-angiotensin 1–7/mas receptor axis in benign prostate hyperplasia. Crit Rev Eukaryot Gene Expr. 2018;28:115–24.

33. Guy J.L., Jackson R.M., Acharya K.R., Sturrock E.D., Hooper N.M., TurnerA.J. Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry. 2003;42:13185–13192.

34. Mizuiri S., Ohashi Y. ACE and ACE2 in kidney disease. World J Nephrol. 2015;4:74–82.

35. Santos R.A., Ferreira A.J., Simões e Silva A.C. Recent advances in the angiotensin-converting enzyme 2–angiotensin (1–7)–Mas axis. Exp Physiol. 2008;93:519–527.

36. Silveira K.D., Barroso L.C., Vieira A.T., Cisalpino D., Lima C.X., Bader M., et al. Beneficial effects of the activation of the angiotensin-(1–7) MAS receptor in a murine model of adriamycin induced nephropathy. PLoS ONE. 2013;8:e66082.

37. Chughtai B., Lee R., Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147–150.

38. Kuzmenko A.V., Kuzmenko V. V., Gyaurgiev T. A., Barannikov I. I. Chronobiological status of patients with chronic prostatitis on the background of prostate adenoma. System analysis and management in biomedical systems. 2017;16(3):513-316. Russian (Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А., Баранников И.И. Хронобиологический статус больных с хроническим простатитом на фоне аденомы простаты. Системный анализ и управление в биомедицинских системах. 2017;16(3):513-516.)

39. Kramer G., Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol. 2006;16: 25–29.

40. Theyer G., Kramer G., Assmann I., Sherwood E., Preinfalk W., Marberger M., et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest.1992;66:96.

41. Kuzmenko A.V., Kuzmenko V. V., Gyaurgiev T.A. Entomological drug adenoprosine for the treatment of patients with benign prostatic hyperplasia and chronic prostatitis. Urology. 2021;1:39-44. Russian (Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Энтомологический препарат аденопросин в лечении пациентов с доброкачественной гиперплазией предстательной железы и хроническим простатитом. Урология. 2021;1:39-44.)

42. Karyakin N.N., Kostina O.V., Galova E.A., Popovicheva A.N., Sosnina L.N., Presnyakova M.V., Makarova E.V., Tulichev A.A. Violations of rheological properties of erythrocytes in patients with COVID-19. Medical almanac. 2020;3(64). Russian (Карякин Н.Н., Костина О.В., Галова Е.А., Поповичева А.Н., Соснина Л.Н., Преснякова М.В., Макарова Е.В., Туличев А.А. Нарушения реологических свойств эритроцитов у пациентов с COVID-19. Медицинский альманах. 2020;3(64).

43. Iba T., Levy J.H., Levi M., Connors J.M., Thachil J. Coagulopathy of coronavirus disease 2019

44. Marchandot B., Sattler L., Jesel L., Matsushita K., Schini-Kerth V., Grunebaum L., Morel O. COVID 19 related coagulopathy: a distinctentity? J Clin Med 2020;9(6):E1651, https://doi.org/10.3390/jcm9061651

45. Giannis D., Ziogas I.A., Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 2020;127:104362, https://doi.org/10.1016/j. jcv.2020.104362

46. Morozov V.G., Khavinson V.H. A new class of biological regulators of multicellular systems-cytomedins. Successes of the modern era. biology. 1983;96(6):339–352. Russian (Морозов В.Г., Хавинсон В.Х. Новый класс биологических регуляторов многоклеточных систем – цитомедины. Успехи совр. биологии. 1983;96(6):339–352).

47. Al-Shukri S.H., Kuzmin I.V., Gorbachev A.G. Prostatic peptide bioregulators in the treatment of urological diseases. Handbook for doctors. SPb., 2011. Russian (Аль-Шукри С.Х., Кузьмин И.В., Горбачев А.Г. Простатические пептидные биорегуляторы в лечении урологических болезней. Пособие для врачей. СПб., 2011).

48. Kuzmin I.V. Vitaprost forte in the treatment of patients with benign prostatic hyperplasia: pathogenetic bases and clinical results. Urologiia. 2019;4:141147. Russian (Кузьмин И.В. Витапрост форте в лечении больных доброкачественной гиперплазией предстательной железы: патогенетические основы и клинические результаты. Урология. 2019;4:141147).

49. Tkachuk V.N., Tkachuk I.N. Effectiveness of vitaprost in patients with chronic prostatitis. Urologiia. 2012;4:88–91. Russian (Ткачук В.Н., Ткачук И.Н. Эффективность витапроста у больных хроническим простатитом. Урология. 2012;4:88–91).

50. Lopatkin N.A., Kamalov A.A., Mazo E.B., Khobotov D.A. The use of Vitaprost tablets for the prevention of exacerbations of chronic abacterial prostatitis. Urologia. 2009;1:29–35. Russian (Лопаткин Н.А., Камалов А.А., Мазо Е.Б., Охотобов Д.А. Применение таблеток препарата Витапроста для профилактики обострений хронического абактериального простатита. Урология. 2009;1:29–35).

51. Kamalov A.A., Efremov E.A., Dorofeev S.D., Panyushkin S.M. The use of the oral form of the drug Vitaprosta ® in the treatment of chronic abacterial prostatitis. Urology. 2006;5:45-51. (Камалов А.А., Ефремов Е.А., Дорофеев С.Д., Панюшкин С.М. Применение пероральной формы препарата Витапроста® в лечении хронического абактериального простатита. Урология. 2006;5:45-51.)

52. Maso E.B., Krivoborodov G.G., Sukhanov S.V. et al. Efficacy and safety of a new dosage form of vitaprost, tablets, in the treatment of patients with prostate adenoma. Urologiia. 2007;6:55–60. Russian (Мазо Е.Б., Кривобородов Г.Г., Суханов С.В. и др. Эффективность и безопасность новой лекарственной формы препарата витапроста, таблетки, в терапии пациентов с аденомой предстательной железы. Урология. 2007;6:55–60).

53. Tkachuk V.N., Tkachuk I.N., Borovets S.Yu. Results of a 12-year study of the effectiveness of vitaprost in patients with chronic prostatitis. Urological reports. 2016;6(4):5-9 Russian (Ткачук В.Н., Ткачук И.Н., Боровец С.Ю. Результаты 12-летнего исследования эффективности витапроста у больных хроническим простатитом. Урологические ведомости. 2016;6(4):5-9) URL: https://cyberleninka.ru/article/n/ rezultaty-12-letnego-issledovaniya-effektivnosti-vitaprosta-u-bolnyh- hronicheskim-prostatitom

54. Miller A.M., Yaroshenko V.P., Soroka P.V., Stakhnev E.Yu. The effectiveness of vitaprost forte in patients with prostate adenoma. Urologiia. 2008;5:50–54. Russian (Миллер А.М., Ярошенко В.П., Сорока П.В., Стахнев Е.Ю. Эффективность витапроста форте у больных аденомой предстательной железы. Урология. 2008;5:50–54).

55. Sitdykova M.E., Zubkov A.Yu. The effectiveness of vitaprost forte in the treatment of prostate adenoma. Urologiia. 2009;6:27–29. Russian (Ситдыкова М. Э., Зубков А.Ю. Эффективность препарата витапрост форте в лечении аденомы предстательной железы. Урология. 2009;6:27–29).

56. Kamalov A.A., Efremov E.A., Dorofeev S.D. et al. Vitaprost forte in the treatment of patients with prostate adenoma. Urology. 2007;3:39–47. Russian (Камалов А.А., Ефремов Е.А., Дорофеев С.Д. и др. Витапрост форте в лечении больных с аденомой простаты. Урология. 2007;3:39–47).

57. Lopatkin N.A., Kamalov A.A., Mazo E.B., Khobotov D.A. The use of Vitaprost tablets for the prevention of exacerbations of chronic abacterial prostatitis. Urologiia. 2009;1:29–35. Russian (Лопаткин Н.А., Камалов А.А., Мазо Е.Б., Охотобов Д.А. Применение таблеток препарата Витапроста для профилактики обострений хронического абактериального простатита. Урология. 2009;1:29–35).